(本文来自第一财经) 辉瑞披露，预计2025年营收约为620亿美元。预计2026年营收为595亿美元至625亿美元。预计2026年调 整后EPS为2.80美元至3.00美元。 (本文来自第一财经) 辉瑞披露，预计2025年营收约为620亿美元。预计2026年营收为595亿美元至625亿美元。预计2026年调 整后EPS为2.80美元至3.00美元。 ...

格隆汇12月16日｜辉瑞(PFE.US)美股盘前跌1.6%。消息面上，辉瑞预计2025年营收约620亿美元，此前 预计为610亿至640亿美元。 ...

Group 1 - Health care stocks have outperformed the S&P 500 over the past three months, with an average gain of 11.55%, but Pfizer's shares have declined by 5% since the start of October [3][8] - Other major pharmaceutical companies like Johnson & Johnson, Regeneron Pharmaceuticals, and Eli Lilly have seen significant gains of nearly 14%, 24%, and 25% respectively during the same period [4] - Pfizer's recent acquisition of obesity biotech Metsera for $10 billion has only resulted in a modest 0.23% gain in its stock since the announcement [4] Group 2 - Pfizer is aiming to expand its presence in the weight loss drug market to recover revenue lost from declining demand for mRNA-based COVID-19 vaccines [5][8] - The company has entered into a $2.1 billion licensing agreement with China's YaoPharma to develop a GLP-1 weight loss pill, which is in early-stage development [5][8] - The agreement includes an upfront payment of $150 million to YaoPharma's parent company, Shanghai Fosun Pharmaceutical, and potential milestone payments of up to $1.94 billion based on the drug's approval progress [6][7]

本文源自：金融界AI电报 辉瑞(PFE.N)预计2026年营收为595亿美元至625亿美元。 ...

Core Viewpoint - Pfizer (PFE.US) projects revenue for 2026 to be between $59.5 billion and $62.5 billion, with adjusted EPS expected to be between $2.80 and $3.00 [1] Revenue Projections - The company anticipates revenue for 2025 to be approximately $62 billion, revised from a previous estimate of $61 billion to $64 billion [1] - The adjusted R&D expenses for 2026 are expected to be between $10.5 billion and $11.5 billion [1]

Core Viewpoint - Pfizer has projected that its profit for 2026 will fall below Wall Street estimates due to anticipated lower sales of its COVID products, resulting in a 1.6% decline in its shares during premarket trading [1] Group 1 - Pfizer's forecast for 2026 profit is lower than Wall Street expectations [1] - The company expects a decrease in sales from its COVID-related products [1] - The announcement led to a 1.6% drop in Pfizer's shares in premarket trading [1]

Core Insights - Pfizer Inc. has provided its full-year 2026 revenue guidance, projecting revenues between $59.5 billion and $62.5 billion, while revising its 2025 revenue guidance to approximately $62.0 billion from a previous range of $61.0 billion to $64.0 billion [2][5] - The 2026 revenue guidance reflects an expected decrease of approximately $1.5 billion from COVID-19 products compared to 2025, along with a similar negative impact due to loss of exclusivity for certain products [2][11] - Pfizer anticipates operational revenue growth of about 4% year-over-year at the midpoint for 2026, excluding COVID-19 and loss of exclusivity products [2] Financial Guidance for 2026 - Adjusted Selling, Informational & Administrative (SI&A) expenses are expected to be between $12.5 billion and $13.5 billion, while Adjusted R&D expenses are projected to be between $10.5 billion and $11.5 billion, leading to total adjusted expenses of $23.0 billion to $25.0 billion for 2026 [3] - Adjusted diluted EPS for 2026 is anticipated to be in the range of $2.80 to $3.00, reflecting stable gross and operating margins compared to 2025 and a higher effective tax rate [4][5] Comparison of Financial Guidance - The revised 2025 financial guidance includes revenues of approximately $62.0 billion, down from the previous range, with COVID-19 product revenues expected to be around $6.5 billion [5] - Adjusted SI&A expenses for 2025 are projected at $13.1 billion to $14.1 billion, while Adjusted R&D expenses are estimated at $10.0 billion to $11.0 billion [5] - The effective tax rate on adjusted income for 2025 is approximately 11%, compared to an expected 15% for 2026 [5] CEO Commentary - The CEO emphasized that 2025 was a year of strong execution and strategic progress, positioning the company for sustainable growth in the post-loss of exclusivity period [7]

天眼查数据显示，Pfizer Inc.成立日期1989年10月07日，法定代表人孟昱，所属行业为化学药品制剂制 造，企业类型为有限责任公司(外国法人独资)，企业规模为中型，参保人数935，注册资本8040万美 元，实缴资本8040万美元，注册地址为辽宁省大连经济技术开发区大庆路22号。股东信息如下： 国家药品监督管理局药品审评中心数据显示，2025年12月16日，Pfizer Inc.的PF-07275315注射液申请已 获受理，受理号为JXSL2500239。 受理号JXSL2500239药品名称PF-07275315注射液药品类型治疗用生物制品申请类型进口注册分类1企业 名称Pfizer Inc.;PFIZER (CHINA) RESEARCH & DEVELOPMENT CO., LTD.;承办日期2025年12月16日 来源：新浪财经-鹰眼工作室 股东名称持股比例认缴出资额认缴出资日期首次持股日期美国晖致企业公司100%8040万美元2017年11 月30日2023年06月09日 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、 ...

Market Performance - On Monday, major U.S. stock indices collectively declined, with the Dow Jones down 0.09% at 48,416.56 points, the Nasdaq down 0.59% at 23,057.41 points, and the S&P 500 down 0.16% at 6,816.51 points [1][2]. Tesla Highlights - Tesla's stock rose over 3%, reaching a nearly one-year high, with a market value increase of over $53 billion in one night [1][4]. - CEO Elon Musk's net worth surpassed $600 billion, making him the first person in history to achieve this milestone [4]. iRobot Situation - iRobot's stock plummeted over 72% after the company filed for bankruptcy protection, planning to be taken over by its main Chinese supplier and manufacturer, leading to its delisting [1][5]. Chinese Stocks Performance - The Nasdaq Golden Dragon China Index fell by 2.17%, with notable declines in stocks such as Baidu (down nearly 5%) and Alibaba (down over 3%) [1][7]. Nasdaq Trading Mechanism - Nasdaq plans to submit a proposal to the SEC to introduce a near-around-the-clock trading mechanism, extending trading hours from 16 to 23 hours per week [1][14]. - The new trading schedule would include two trading periods: a daytime session starting at 4 AM and ending at 8 PM, and a night session from 9 PM to 4 AM [14][15].

Group 1 - Broadcom shares fell over 5%, while Apple and Amazon rose over 1%, and Tesla increased by over 3%, adding $53.7 billion (approximately 378.6 billion RMB) to its market value [1] - Elon Musk's net worth reached $677 billion, making him the first person in history to surpass the $600 billion mark, previously no one had crossed $500 billion [3] - iRobot officially declared bankruptcy with a stock value of zero after finalizing its restructuring plan on December 15, resulting in a 72.69% drop in its shares [3] Group 2 - The Nasdaq Golden Dragon China Index fell by 2.17%, with major Chinese stocks declining; Baidu dropped nearly 5%, and Alibaba, Xpeng Motors, and others fell over 3% [5] - WTI crude oil futures decreased by 1.08% to $56.82 per barrel, while Brent crude oil futures fell by 0.92% to $60.56 per barrel [6] - Bitcoin fell below $86,000 for the first time in two weeks, dropping 3.3% to $85,578, approximately 30% down from its record high of over $126,000 [6][7] Group 3 - Over the past 24 hours, more than 190,000 traders were liquidated, resulting in a total loss of $670 million (approximately 4.7 billion RMB) [9] - The New York Federal Reserve's manufacturing index unexpectedly shrank to -3.9 in December, indicating a contraction in economic activity, significantly below the expected median of 10 [11][13] - Federal Reserve Governor Milan suggested that the current monetary policy is too tight and advocated for a faster pace of rate cuts, citing signs of a cooling labor market [13]